ReviewPediatric nephrology (Berlin, Germany)2020
Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways.
Review in Pediatric nephrology (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review.International journal of molecular sciences · 2021Pooled it
- A comprehensive insight into NETosis-extracellular vesicle crosstalk in autoimmune diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- Tubulointerstitial nephritis in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2025Review
- Evaluation of the Nephroprotective Activity of Crude Extract Root ofJournal of toxicology · 2025Article
- More on the invisibility of chronic kidney disease… and counting.Clinical kidney journal · 2022Article
- Prognosis of severe drug-induced acute interstitial nephritis requiring renal replacement therapy.Renal failure · 2021Article
- The significance of the hemalexin C1q, RBP, and urinary NAG levels in the diagnosis and prognosis of children with purpura nephritis.American journal of translational research · 2021Article
- New Biomarkers in Acute Tubulointerstitial Nephritis: A Novel Approach to a Classic Condition.International journal of molecular sciences · 2020Review
- Arachidonic Acid Metabolism and Kidney Inflammation.International journal of molecular sciences · 2019Review
- Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury.Journal of advanced pharmaceutical technology & researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 250 drugs carry a small but important dose-independent risk of initiating a delayed-type hypersensitivity reaction that leads to acute tubulointerstitial nephritis (TIN). Clinical manifestations are often non-specific, making epidemiological studies challenging. In severe cases, if cessation of the offending drug is not followed by a prompt improvement in renal function, corticosteroid therapy appears to enhance renal recovery rates. Other drugs, classified as potential nephrotoxins, may induce dose-dependent acute tubular necrosis. Studies over the past decade have identified a unique form of tubular cell death called "necroptosis" that is accompanied by a specific and significant interstitial inflammatory response to certain insults, including some nephrotoxins. Insights into the molecular basis of this necroinflammatory pathway have emerged. There is still a paucity of pediatric data on these two distinct types of drug-induced TIN. Early recognition is essential to minimize the risk of chronic kidney damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.